The US FDA/CDRH is proposing to harmonize the current Quality System Regulation (QSR) for medical devices (21 CFR 820) by converging its requirements with requirements used by many other regulatory authorities. ISO 13485, into a new device Quality Management System Regulation (QMSR).
This webinar will examine the 15 subparts of the Medical Device CGMPs, 21 CFR 820, the Quality System Regulation, compared against the current version of ISO 13485:2016, with its 8 subparts. The substantial areas of similarity will be discussed; then the areas of FDA concern and proposed solutions; and the addition of those requirements necessary to remain in alignment with the US FDA's Federal Food, Drug & Cosmetic Act.
The structure of the proposed QMSR will be discussed: 820.1 Scope; 820.3 Definitions; 820.7 Incorporation (ISO 13485:2016) by reference; 820.10 Requirements for a quality management system - Links additional FDA requirements such as MDR, UDI, Corrections & Removals, and Tracking; applicability of Design and Development activities; 820.15 Clarification of concepts - Correlates concepts in ISO 13485 to FDA; 820.35 Control of records - Supplements record keeping activities, signature and date, complaint/servicing records, UDI, and confidentiality; and 820.45 Device labeling and packaging controls. The primary areas of difference are Document Control, Labeling and Packaging Control, Records, and Servicing. These will be discussed in the webinar as well. There will be a one-year transition period.
Areas Covered in the Webinar:-
Why Should You Attend:-
FDA/CDRH is proposing to harmonize the current Quality System (QS) regulation for medical devices (21 CFR 820) by converging its requirements with requirements used by many other regulatory authorities. Revisions to Part 820 will replace most of the existing regulation with an incorporation by reference (IBR) to the 2016 edition of" ISO 13485 - Medical Devices - Quality Management Systems Requirements for Regulatory Purposes". The requirements in ISO 13485:2016 are substantially similar to the current requirements of Part 820, the QSR. Differences will be explained or reconciled, and the few areas where ISO 13485 is considered weak by the FDA will be strengthened in the proposed US QMSR.
Who Will Benefit:-
All personnel involved in the U.S. FDA-regulated medical device spec development and manufacturing environments. Especially those involved in new medical device/combination product development, line extensions, and incremental product improvements; CGMP compliance, and the documentation of these actions in harmony with the regulations.
* Download the Order Form
* For 6+ attendees call us at + 1 (844) 449-0244 or mail us at cs@currentwebinar.com
John E. Lincoln is the Principal of J. E. Lincoln and Associates LLC, a consulting company, with over 32 years of experience in U.S. FDA-regulated industries, 18 of which as a full-time independent FDA-regulated industry consultant. Mr. Lincoln has worked with companies from start-up to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China, and Taiwan. He specializes in quality assurance, regulatory affairs, QMS / CGMP audits, problem remediation and FDA responses, new/changed product 510(k)s, process/product/equipment including QMS and software validations, ISO 14971 product risk management files/reports, Design Control / Design History Files, Technical Files. He’s held positions in Manufacturing Engineering, QA, QAE, and Regulatory Affairs, to the level of Director and VP (R&D).